-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Vistagen Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q3 2012 to Q2 2024.
- Vistagen Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2024 was -$10.7M, a 55.5% decline year-over-year.
- Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$29.4M, a 50.4% increase from 2022.
- Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$59.2M.
- Vistagen Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2013 was -$2.97M, a 77% increase from 2012.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)